Last reviewed · How we verify

ARV bitherapie — Competitive Intelligence Brief

ARV bitherapie (ARV bitherapie) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy. Area: Infectious Disease.

phase 3 Antiretroviral combination therapy Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ARV bitherapie (ARV bitherapie) — ANRS, Emerging Infectious Diseases. ARV bitherapie is a two-drug antiretroviral combination regimen designed to suppress HIV replication by targeting viral reverse transcriptase and/or protease enzymes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ARV bitherapie TARGET ARV bitherapie ANRS, Emerging Infectious Diseases phase 3 Antiretroviral combination therapy
DTG/3TC/ABC + ELV/COBI/FTC/TAF DTG/3TC/ABC + ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV integrase, HIV reverse transcriptase
TDF/3TC/EFV TDF/3TC/EFV Peking Union Medical College Hospital marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
Combivir+Reyataz Combivir+Reyataz Hospital Clinic of Barcelona marketed Antiretroviral combination therapy (NRTI + protease inhibitor) HIV reverse transcriptase; HIV protease
ELV/COBI/FTC/TAF ELV/COBI/FTC/TAF Fundacion SEIMC-GESIDA marketed Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster) HIV integrase, HIV reverse transcriptase
didanosine + lamivudine + efavirenz didanosine + lamivudine + efavirenz Clinical Trial Agency of HIV Study Group marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
TDF/3TC/EFV or DTG or NVP TDF/3TC/EFV or DTG or NVP MU-JHU CARE marketed Antiretroviral combination therapy (NRTI + NNRTI or INSTI) HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy class)

  1. ANRS, Emerging Infectious Diseases · 1 drug in this class
  2. Chang Gung Memorial Hospital · 1 drug in this class
  3. Danish HIV Research Group · 1 drug in this class
  4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
  5. Hospital Nossa Senhora da Conceicao · 1 drug in this class
  6. Kristine Patterson, MD · 1 drug in this class
  7. PETHEMA Foundation · 1 drug in this class
  8. University of Alberta · 1 drug in this class
  9. University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARV bitherapie — Competitive Intelligence Brief. https://druglandscape.com/ci/arv-bitherapie. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: